Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

r, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral T
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, ... an update on its pipeline and new product ... expects to initiate a Phase 2a study of ... developed for the management of patients with acute ... Staccato -based product candidates for development - ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
(Date:8/1/2014)... 2014 A new study published ... may contribute to the development of colorectal cancer in ... The study was authored by Alberto Martin of the ... cause intestinal cells to multiply and create tumors in ... , “What’s interesting about this study,” said Shahab ...
(Date:8/1/2014)... Canadian, OK (PRWEB) August 01, 2014 ... graduate from the program at the drug rehab center ... in the year 2001, Narconon Arrowhead is the flagship ... come from across the United States for services there. ... the center has recent outcome studies as well as ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... recently announced the addition of a comprehensive report ... titled ‘Infusion System Market (Large Volume, Disposable, Syringe, ... Share, Growth, Trends And Forecast, 2013 – 2019’ ... website http://www.transparencymarketresearch.com . , To begin with, ...
(Date:8/1/2014)... HealthDay Reporter , THURDAY, July ... healthier than school cafeteria fare, a new study suggests. ... lunches third and fourth graders brought from home met three ... "Our findings are similar to results of other studies of ... that high-calorie packaged foods and beverages are more common than ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although older women ... make asthma care a priority, according to a new study. ... from asthma much more than men over 65," concluded Dr. ... of Allergy, Asthma and Immunology (ACAAI), in an organization news ... age 65 years and older is nearly four times higher ...
Breaking Medicine News(10 mins):Health News:Carbs May Contribute to Colon Cancer 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Older Women With Asthma Face Worse Health Outcomes 2
... April 22 Aida,Pharmaceuticals, Inc. (OTC Bulletin ... investor-focused corporate synopsis on its English,language website, ... as a,pdf document. The synopsis details Aida ... line, the drugs in its,development pipeline, as ...
... leads to adverse reactions identified, officials add , , MONDAY, ... now been found in at least 10 countries, not ... to ensure the safety of the blood thinner, U.S. ... contaminated lots of the blood thinner have been traced ...
... Available in Smaller Package for Healthy Snacking, MINDEN, ... the maker of the award-winning Detour(R) bar, today announced,the ... their top,selling Detour Caramel Peanut Bar(TM). The snack size ... choice for energy seekers living a,healthy lifestyle. With seven ...
... The American College of Allergy,Asthma & Immunology ... surveys that highlight the importance of improving care ... and other important,information for physicians and patients are ... like Sepracor who are,committed to driving the dialogue ...
... SAN JUAN, Puerto Rico, April 22 Triple-S,Management Corporation ... plans,to release financial results for the first quarter ended ... 2008. Ramon M. Ruiz-Comas, President and,Chief Executive Officer, and ... host a conference call to discuss these,results and the ...
... Formation Capital, LLC is,pleased to announce that ... joined the company as Senior Executive Vice President ... be leading the day-to-day,operations and direction of the ... leading change, building shareholder value, and managing Board,and ...
Cached Medicine News:Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:FDA: Contaminated Heparin Found in 11 Countries 2Health News:FDA: Contaminated Heparin Found in 11 Countries 3Health News:FDA: Contaminated Heparin Found in 11 Countries 4Health News:Detour(R) Unveils Snack Size Protein Bar 2Health News:Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast 2Health News:Damian Dell'Anno Joins Formation Capital as Chief Operating Officer 2
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
S.O.C. Medium...
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: